Lightmix kit hdv

Hepatitis B surface antigen (HBsAg) was identified and determined through standard quantitative chemiluminescent micro-particle immunoassay (ARCHITECT HBsAg, Abbott Diagnostics) or qualitative assay (Abbott Laboratories, North Chicago, IL, USA). Hepatitis B e-antigen (HBeAg) was identified and determined using enzyme-linked immunosorbent assay kits (Abbott Laboratories). HBV DNA from the serum was determined using a standardized, automated quantitative PCR assay (COBAS TaqMan HBV test, Roche Diagnostics, Branchburg, NJ; detection limit 12 IU/mL) [33 (link)]. Anti-HDV immunoglobulin G (IgG), examined by using an anti-HDV enzyme-linked immunosorbent assay kit (General Biologicals Corporation, Taiwan) [4 (link)], was checked prior to initiating NUCs therapy, and patient serology with anti-HDV seropositivity was monitored annually from there on. HDV RNA was examined in patients seropositive for anti-HDV using a LightMix Kit HDV (Berlin, Germany) on a Roche LightCycler (detecting limit: 10 copies per mL) [18 (link)].

Anti‐HDV IgG antibody was determined using the anti‐HDV ELISA kit (General Biologicals Corporation, Taiwan). Serum HDV RNA was quantified using a LightMix Kit HDV (Berlin, Germany) on a Roche LightCycler (detection limit: 10 copies/ml)^{15 (link)}.